Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-19983 |
Brand: | MCE |
CAS: | 1453208-66-6 |
MDL | - |
---|---|
Molecular Weight | 407.37 |
Molecular Formula | C18H19F2N5O4 |
SMILES | OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1 |
FGFR1 0.47 nM (IC 50 ) |
FGFR2 0.6 nM (IC 50 ) |
FGFR3 0.74 nM (IC 50 ) |
FGFR4 3.5 nM (IC 50 ) |
ASP5878 shows potent antiproliferative activity in most human HCC cell lines
[1]
.
ASP5878 inhibits FGFR4 phosphorylation in a concentration-dependent manner. ASP5878 treatment results in the suppression of phosphorylation, mobility shift of FRS2, and suppression of ERK phosphorylation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | Human HCC cell lines. |
Concentration: | 0-1000 nM. |
Incubation Time: | 5 days. |
Result: |
HuH-7, Hep3B2.1-7, and JHH-7 cell lines exhibited potent sensitivity to ASP5878, with IC
50
values of 27, 8.5, and 21 nmol/L, respectively.
The growth inhibition rate of HLF was 64% and those of other ASP5878-sensitive cell lines were higher than 95% at 1000 nM. |
ASP5878 (3 mg/kg, orally, once daily) shows antitumor activity in a Hep3B2.1-7 subcutaneous xenograft and HCC orthotopic xenograft mouse model
[1]
.
ASP5878 induces shrinkage of FGF19-expressing HCC xenograft model
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Four-week-old male nude mice (CAnN.Cg-Foxn1nu/CrlCrlj [nu/nu]) (Hep3B2.1-7 cells inoculated subcutaneously) [1] . |
Dosage: | 3 mg/kg. |
Administration: | Orally once daily from days 14 to 52. |
Result: |
Induced tumor regression by 9% and 88% at 1 and 3 mg/kg, respectively, without affecting the body weight for 14 days.
Induced the suppression of FGFR4 phosphorylation, mobility shift of FRS2, and suppression of ERK phosphorylation. |
Animal Model: | HCC orthotopic xenograft model (mouse) [1] . |
Dosage: | 3 mg/kg. |
Administration: | Orally once daily for 24 days. |
Result: |
Exhibited a lower tumor burden than vehicle- and sorafenibtreated mice.
Induced sustained tumor regression without tumor regrowth. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT02038673 | Astellas Pharma Inc|Astellas Pharma Global Development, Inc. |
Solid Tumors
|
November 5, 2013 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 250 mg/mL ( 613.69 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.4548 mL | 12.2739 mL | 24.5477 mL |
5 mM | 0.4910 mL | 2.4548 mL | 4.9095 mL |
10 mM | 0.2455 mL | 1.2274 mL | 2.4548 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.11 mM); Clear solution
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.